Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours

BACKGROUND: This study sought to determine the safety of single agent capecitabine, a pro-drug of 5FU, in patients with metastatic non-pancreatic neuroendocrine tumours (NETs). METHODS: Multicentre phase II, first-line study design. Oral capecitabine was administered on days 1–14 of 3-week cycles. R...

Descripción completa

Detalles Bibliográficos
Autores principales: Medley, L, Morel, A N, Farrugia, D, Reed, N, Hayward, N, Davies, J M, Kirichek, O, Thakker, R V, Talbot, D C
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068509/
https://www.ncbi.nlm.nih.gov/pubmed/21386841
http://dx.doi.org/10.1038/bjc.2011.76
_version_ 1782201259108859904
author Medley, L
Morel, A N
Farrugia, D
Reed, N
Hayward, N
Davies, J M
Kirichek, O
Thakker, R V
Talbot, D C
author_facet Medley, L
Morel, A N
Farrugia, D
Reed, N
Hayward, N
Davies, J M
Kirichek, O
Thakker, R V
Talbot, D C
author_sort Medley, L
collection PubMed
description BACKGROUND: This study sought to determine the safety of single agent capecitabine, a pro-drug of 5FU, in patients with metastatic non-pancreatic neuroendocrine tumours (NETs). METHODS: Multicentre phase II, first-line study design. Oral capecitabine was administered on days 1–14 of 3-week cycles. RESULTS: Treatment was safe and well tolerated. Common toxicities were diarrhoea and fatigue. CONCLUSION: The study provides evidence to support the use of capecitabine as a substitute for infusional 5FU in the management of NETs.
format Text
id pubmed-3068509
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-30685092012-03-29 Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours Medley, L Morel, A N Farrugia, D Reed, N Hayward, N Davies, J M Kirichek, O Thakker, R V Talbot, D C Br J Cancer Short Communication BACKGROUND: This study sought to determine the safety of single agent capecitabine, a pro-drug of 5FU, in patients with metastatic non-pancreatic neuroendocrine tumours (NETs). METHODS: Multicentre phase II, first-line study design. Oral capecitabine was administered on days 1–14 of 3-week cycles. RESULTS: Treatment was safe and well tolerated. Common toxicities were diarrhoea and fatigue. CONCLUSION: The study provides evidence to support the use of capecitabine as a substitute for infusional 5FU in the management of NETs. Nature Publishing Group 2011-03-29 2011-03-08 /pmc/articles/PMC3068509/ /pubmed/21386841 http://dx.doi.org/10.1038/bjc.2011.76 Text en Copyright © 2011 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Short Communication
Medley, L
Morel, A N
Farrugia, D
Reed, N
Hayward, N
Davies, J M
Kirichek, O
Thakker, R V
Talbot, D C
Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours
title Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours
title_full Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours
title_fullStr Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours
title_full_unstemmed Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours
title_short Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours
title_sort phase ii study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068509/
https://www.ncbi.nlm.nih.gov/pubmed/21386841
http://dx.doi.org/10.1038/bjc.2011.76
work_keys_str_mv AT medleyl phaseiistudyofsingleagentcapecitabineinthetreatmentofmetastaticnonpancreaticneuroendocrinetumours
AT morelan phaseiistudyofsingleagentcapecitabineinthetreatmentofmetastaticnonpancreaticneuroendocrinetumours
AT farrugiad phaseiistudyofsingleagentcapecitabineinthetreatmentofmetastaticnonpancreaticneuroendocrinetumours
AT reedn phaseiistudyofsingleagentcapecitabineinthetreatmentofmetastaticnonpancreaticneuroendocrinetumours
AT haywardn phaseiistudyofsingleagentcapecitabineinthetreatmentofmetastaticnonpancreaticneuroendocrinetumours
AT daviesjm phaseiistudyofsingleagentcapecitabineinthetreatmentofmetastaticnonpancreaticneuroendocrinetumours
AT kiricheko phaseiistudyofsingleagentcapecitabineinthetreatmentofmetastaticnonpancreaticneuroendocrinetumours
AT thakkerrv phaseiistudyofsingleagentcapecitabineinthetreatmentofmetastaticnonpancreaticneuroendocrinetumours
AT talbotdc phaseiistudyofsingleagentcapecitabineinthetreatmentofmetastaticnonpancreaticneuroendocrinetumours

Ejemplares similares